

REMARKS

The present invention relates to 1-aryl- or 1-alkylsulfonylbenzazole compounds of formula I, and the therapeutic use thereof for the treatment of CNS disorders related to or affected by the 5-hydroxytryptamine-6 receptor.

Claims 1-20 are pending in this application. Claims 1, 8 and 15 have been amended.


Claims 10-14 and 20 have been withdrawn by the Examiner. Examiner has pointed out that rejoinder will be permitted when a product claim is found allowable.

Claims 1-9 and 15-19 have been objected to as containing non-elected subject matter. Examiner has suggested the claims be amended to be limited to the elected invention. In a telephone conversation on December 6, 2004, Examiner agreed the scope of the elected invention includes cycloheteroalkyl in the definition of R₃ and R₄.

Applicants have amended claims 1, 8 and 15 to exclude all non-elected subject matter. Applicants reserve the right to file a divisional application on the non-elected subject matter.

In conclusion, Applicants believe that the Examiner's objection to the claims have been overcome in view of the amendments to the claims and in view of the foregoing. Applicants respectfully request the Examiner to enter the above amendments, consider the above remarks, withdraw the objection and allow the application.

Respectfully submitted,


Barbara L. Lences
Agent for Applicants
Reg. No. 41,148

Wyeth
Patent Law Department
Five Giralta Farms
Madison, NJ 07940
Tel. No. (732) 274-4678